Wells Fargo lowered the firm’s price target on Insmed to $175 from $208 and keeps an Overweight rating on the shares. The firm believes the pulmonary hypertension market is poised to change. With key opinion leader feedback from a Respimat developer, and counter to current market sentiment, Wells sees Liquidia’s (LQDA) L606 as competitive with Insmed’s (INSM) TPIP.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM: